The Company’s board of directors has authorized implementation of a reverse stock split at a ratio of one-for-ten, which the Company expects to take effect after the close of trading on Wednesday, May 10, 2006.
targetedgenetics.com
“Our management team and board of directors believe that maintaining our listing on the Nasdaq is in the best interest for the Company and our shareholders by providing a broader market for trading our common stock and by increasing our ability to execute strategic or financing transactions,” said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics Corporation. “We believe that a higher stock price may help to generate greater interest in our securities among investors and analysts, in particular with upcoming data from our inflammatory arthritis program being presented at several scientific venues this year. This action may also help us attract and retain quality employees.”
Emphasis added.
They never give up, and that's great--Tgen keeps doing
it's bit to advance AAV and such, rough on shareholders,
but you have to give them credit for staying alive.
I rode some Global Crossing stock right down to zero,
but at least there is closure when they stop trading.
This one has been a little rough on you folks.
If you register at ASGT you can check out some abstracts
for the May 31-June 4th annual meeting.
Just a quick glance expanding out the AAV sections
each day--abstracts 1-10, 101-120, 484-513, 739-746,
1062-1067 all have something to do with AAV.
asgt.org
I only happened to glance at the very last one,
which happened to be a AAV6 TNF-blocking abstract.
So if you peruse the abstracts, you could start with
that one ane work backward. It was some french hospital
not Tgen however.
They're sure a plucky little company and maybe
they'll have some luck with their arthritis experiment.
Good luck--and thanks for sharing your notes from the
annual meeting! |
